Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po-Hsin Lee

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancers|January 8, 2025
Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M MutationMu-Han Peng, Yen-Hsiang Huang, Kuo-Hsuan Hsu, et al.
Archives of Biochemistry and Biophysics|October 8, 2025
Lauryl gallate induces apoptosis via p38-MAPK phosphorylation and autophagy in chemoresistant human lung cancer cellsYen-Hsiang Huang, Shur-Hueih Cherng, Ling-Yen Chiu, et al.
Therapeutic Advances in Medical Oncology|November 1, 2024
Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancerWei-Fan Ou, Kuo-Hsuan Hsu, Jeng-Sen Tseng, et al.
Oncotargets and Therapy|July 1, 2025
Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and RadiotherapyTzu-I Chuang, Kuo-Hsuan Hsu, Po-Hsin Lee, et al.
Scientific Reports|May 1, 2021
Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitorsPo-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, et al.
Journal of Clinical Medicine|January 8, 2023
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor TreatmentPo-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, et al.
Medicine|June 17, 2022
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)Jia-Jun Wu, Po-Hsin Lee, Zhe-Rong Zheng, et al.
Plos One|August 18, 2022
Various impacts of driver mutations on the PD-L1 expression of NSCLCCheng-Hsiang Chu, Yen-Hsiang Huang, Po-Hsin Lee, et al.
JCO Precision Oncology|September 30, 2024
Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in TaiwanPo-Hsin Lee, I-Chieh Chen, Yi-Ming Chen, et al.
Journal of Advanced Research|July 7, 2026
Study of benign prostatic hyperplasia and androgen pathway manipulation on lung cancer survivalsPo-Hsin Lee, Pang-Ting Cheng, Ayse Celik, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancers|January 8, 2025
Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M MutationMu-Han Peng, Yen-Hsiang Huang, Kuo-Hsuan Hsu, et al.
Archives of Biochemistry and Biophysics|October 8, 2025
Lauryl gallate induces apoptosis via p38-MAPK phosphorylation and autophagy in chemoresistant human lung cancer cellsYen-Hsiang Huang, Shur-Hueih Cherng, Ling-Yen Chiu, et al.
Therapeutic Advances in Medical Oncology|November 1, 2024
Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancerWei-Fan Ou, Kuo-Hsuan Hsu, Jeng-Sen Tseng, et al.
Oncotargets and Therapy|July 1, 2025
Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and RadiotherapyTzu-I Chuang, Kuo-Hsuan Hsu, Po-Hsin Lee, et al.
Scientific Reports|May 1, 2021
Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitorsPo-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, et al.
Journal of Clinical Medicine|January 8, 2023
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor TreatmentPo-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, et al.
Medicine|June 17, 2022
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)Jia-Jun Wu, Po-Hsin Lee, Zhe-Rong Zheng, et al.
Plos One|August 18, 2022
Various impacts of driver mutations on the PD-L1 expression of NSCLCCheng-Hsiang Chu, Yen-Hsiang Huang, Po-Hsin Lee, et al.
JCO Precision Oncology|September 30, 2024
Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in TaiwanPo-Hsin Lee, I-Chieh Chen, Yi-Ming Chen, et al.
Journal of Advanced Research|July 7, 2026
Study of benign prostatic hyperplasia and androgen pathway manipulation on lung cancer survivalsPo-Hsin Lee, Pang-Ting Cheng, Ayse Celik, et al.
Pageof 3